CAR T Cell Therapy in Solid Tumors: Lessons From Early‐Phase Clinical Trials and Biological Barriers to Efficacy
Hematological Oncology · 2026
DOI: 10.1002/hon.70209 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hematological Oncology, 2026. Verfasst von Kasie Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: MD Anderson Mays Cancer Center at UT Health San Antonio, San Antonio, Texas, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Neoplasms, Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 263 Literaturangaben. Gefördert von: NCI NIH HHS, Morrison Trust, ThriveWell Cancer Research Foundation.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of select hematologic malignancies, where disease accessibility, well‐defined lineage antigens, and clinically manageable target cell depletion have enabled more durable responses. However, translation to solid tumors has been far more limited due to the structural, metabolic, and immunologic barriers that are less prominent in many blood cancers. This review uses hematologic malignancies as the standard for CAR T cell therapy success while synthesizing mechanistic insights from preclinical models and emerging data from early‐phase solid tumor trials. We define how antigen heterogeneity, impaired trafficking, metabolic suppression, immunosuppressive signaling, and on‐target, off‐tumor toxicity limit CAR T cell infiltration, persistence, and function in solid tumors. We also highlight recurring clinical patterns indicating that antitumor activity is most achievable when tumor‐enriched antigens are targeted, delivery strategies overcome physical barriers, and CAR T cells are engineered to resist exhaustion and suppression within hostile microenvironments. By evaluating next‐generation approaches, including cytokine armoring, multi‐antigen and logic‐gated recognition, regional delivery, and regulatable safety circuits, we propose a model for rational CAR T cell design tailored to solid tumor biology while informed by the principles underlying hematologic success. These insights support context‐dependent engineered immunotherapies capable of extending the durability and safety achieved in blood cancers to solid malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MD Anderson Mays Cancer Center at UT Health San Antonio, San Antonio, Texas, USA.
- Department of Cell Systems and Anatomy, UT Health San Antonio, San Antonio, Texas, USA.
- Department of Biology, Trinity University, San Antonio, Texas, USA.
- Department of Thoracic Surgery, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Department of Pathology and Laboratory Medicine, UT Health San Antonio, San Antonio, Texas, USA.
ORCID-Profile: Kasie Liu
Förderung
- NCI NIH HHS
- Morrison Trust
- ThriveWell Cancer Research Foundation
- Mays Cancer Center
- NIH HHS
- Evans Medical Foundation
- American Cancer Society
- National Cancer Institute
Zitieren
APA
Liu, K., Pham, V. T., Fu, S., Sun, L., & Huang, G. (2026). CAR T Cell Therapy in Solid Tumors: Lessons From Early‐Phase Clinical Trials and Biological Barriers to Efficacy. Hematological Oncology. https://doi.org/10.1002/hon.70209
Vancouver
Liu K, Pham VT, Fu S, Sun L, Huang G. CAR T Cell Therapy in Solid Tumors: Lessons From Early‐Phase Clinical Trials and Biological Barriers to Efficacy. Hematological Oncology. 2026. doi:10.1002/hon.70209
BibTeX
@article{Liu2026,
author = {Liu, Kasie and Pham, Vincent Truong and Fu, Shaozi and Sun, LuZhe and Huang, Gang},
title = {CAR T Cell Therapy in Solid Tumors: Lessons From Early‐Phase Clinical Trials and Biological Barriers to Efficacy},
journal = {Hematological Oncology},
year = {2026},
doi = {10.1002/hon.70209}
}
EUVIMED